Omicron subvariants dominate 95% of sequenced cases while most new lineages show no growth advantage

The New Scientist article correctly notes that routine emergence of variants does not equate to threat escalation, but understates the quantitative filtering already occurring via competitive fitness. Real-time phylogenetic tracking by Nextstrain and the UK Health Security Agency demonstrates that only lineages acquiring both immune escape and replicative advantages displace predecessors. Most mutations remain deleterious or neutral under current population immunity landscapes shaped by vaccination and prior infection.

Context from the CDC’s Nowcast and WHO technical reports reveals that XBB.1.5 and JN.1 each required specific combinations of spike substitutions (e.g., L455S, F456L) to achieve dominance; isolated mutations rarely confer such phenotypes. This pattern explains why thousands of daily deposited sequences produce few sustained transmission chains. The missed analytical point is that current immunity breadth, not variant novelty per se, now determines replacement probability.

What comes next hinges on whether a lineage simultaneously improves ACE2 binding affinity and evades antibody recognition at levels exceeding JN.1. Continued investment in wastewater and hospital sentinel sequencing remains essential because early growth-rate signals, not sequence counts alone, predict public-health impact.